BR0307123A - Derivados de piperazina - Google Patents

Derivados de piperazina

Info

Publication number
BR0307123A
BR0307123A BR0307123-5A BR0307123A BR0307123A BR 0307123 A BR0307123 A BR 0307123A BR 0307123 A BR0307123 A BR 0307123A BR 0307123 A BR0307123 A BR 0307123A
Authority
BR
Brazil
Prior art keywords
alkyl
hydrogen
integer
nitrogen
formula
Prior art date
Application number
BR0307123-5A
Other languages
English (en)
Other versions
BRPI0307123B8 (pt
BRPI0307123B1 (pt
Inventor
Giuseppe Alvaro
Romano Di Fabio
Maria Elvira Tranquillini
Simone Spada
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0307123A publication Critical patent/BR0307123A/pt
Publication of BRPI0307123B1 publication Critical patent/BRPI0307123B1/pt
Publication of BRPI0307123B8 publication Critical patent/BRPI0307123B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE PIPERAZINA". A presente invenção diz respeito a piperidina derivados de fórmula (I): R representa halogênio ou alquila C~ 1-4~; R~ 1~ representa alquila C~ 1-4~; R~ 2~ ou R~ 3~ independentemente representa hidrogênio ou alquila C~ 1-4~; R~ 4~ representa trifluorometila, alquila C~ 1-4~, alcóxi C~ 1-4~, trifluorometóxi ou halogênio; R~ 5~ representa hidrogênio, alquila C~ 1-4~ ou cicloalquila C~ 3-7~; R~ 6~ é hidrogênio e R~ 7~ é um radical de fórmula (W): R~ 6~ é um radical de fórmula (W) e R~ 7~ é hidrogênio; X representa CH~ 2~, NR~ 5~ ou 0; Y representa nitrogênio e Z é CH ou Y representa CH e Z é nitrogênio; A representa C(O) ou S(O)q, desde que, quando Y for nitrogênio e Z for CH, A não seja S(O)q; m é zero ou um número inteiro de 1 para 3; n é um número inteiro de 1 para 3; p e q são independentemente um número inteiro de 1 a 2; e sais ou solvatos farmaceuticamente aceitáveis destes. O processo para sua preparação e seu uso no tratamento de condição mediada por taquicininas.
BRPI0307123A 2002-02-08 2003-02-10 derivados de piperidina BRPI0307123B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0203020.3A GB0203020D0 (en) 2002-02-08 2002-02-08 Chemical compounds
GB0203020.3 2002-02-08
PCT/EP2003/001308 WO2003066635A1 (en) 2002-02-08 2003-02-10 Piperidine derivatives

Publications (3)

Publication Number Publication Date
BR0307123A true BR0307123A (pt) 2004-12-07
BRPI0307123B1 BRPI0307123B1 (pt) 2018-06-19
BRPI0307123B8 BRPI0307123B8 (pt) 2021-05-25

Family

ID=9930717

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307123A BRPI0307123B8 (pt) 2002-02-08 2003-02-10 derivados de piperidina

Country Status (27)

Country Link
US (3) US7189713B2 (pt)
EP (2) EP1666465B1 (pt)
JP (1) JP4488743B2 (pt)
KR (1) KR101011316B1 (pt)
CN (1) CN1319973C (pt)
AR (1) AR038818A1 (pt)
AT (2) ATE394375T1 (pt)
AU (1) AU2003205753B9 (pt)
BR (1) BRPI0307123B8 (pt)
CA (1) CA2475619C (pt)
CO (1) CO5611152A2 (pt)
DE (2) DE60320865D1 (pt)
DK (1) DK1472256T3 (pt)
ES (2) ES2250870T3 (pt)
GB (1) GB0203020D0 (pt)
HK (1) HK1072251A1 (pt)
IL (2) IL162765A0 (pt)
IS (1) IS2402B (pt)
MX (1) MXPA04006791A (pt)
MY (1) MY130411A (pt)
NO (1) NO329379B1 (pt)
NZ (1) NZ533785A (pt)
PL (1) PL211082B1 (pt)
RU (1) RU2336276C2 (pt)
TW (1) TWI291466B (pt)
WO (1) WO2003066635A1 (pt)
ZA (1) ZA200404842B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
EP1594574A2 (en) * 2003-01-27 2005-11-16 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP5078869B2 (ja) * 2005-03-08 2012-11-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニューロキニン（ｎｋ１）拮抗物質としてのジアザ−スピロ−［４．４］−ノナン誘導体
AR058805A1 (es) * 2005-09-09 2008-02-27 Smithkline Beecham Corp Derivados biciclicos de piridina utiles como agentes antipsicoticos
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
CA2636946A1 (en) * 2006-01-11 2007-07-19 Merck And Co., Inc. Fused triazole tachykinin receptor antagonists
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010530874A (ja) * 2007-06-22 2010-09-16 メルク・シャープ・エンド・ドーム・コーポレイション ６，５−ピロロピペリジンタキキニン受容体アンタゴニスト
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
US9181259B2 (en) * 2012-02-22 2015-11-10 Leo Pharma A/S Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists
WO2014057003A1 (en) 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses
CN105579456A (zh) * 2013-08-20 2016-05-11 利奥制药有限公司 新型神经激肽1受体拮抗剂化合物ii
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
RS59313B1 (sr) * 2016-01-08 2019-10-31 Nerre Therapeutics Ltd Orvepitant za lečenje hroničnog kašlja
KR20200002899A (ko) 2017-04-10 2020-01-08 체이스 테라퓨틱스 코포레이션 시누클레인병변을 치료하기 위한 nk1-길항제 배합물 및 방법
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
WO2021245512A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
KR910009880B1 (ko) 1983-07-25 1991-12-03 가부시기가이샤 히다찌세이사꾸쇼 인터레이스된 텔레비젼 신호중의 화상의 움직임 검출회로
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
GB9106127D0 (en) 1991-03-22 1991-05-08 Byrne Charles M Spread
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
PT533280E (pt) 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
TW397831B (en) 1994-07-15 2000-07-11 Meiji Seika Kaisha The anti-platelet-agglutination hexahydrogenated pyridine and its derivatives
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
WO1996003378A1 (fr) 1994-07-26 1996-02-08 Sankyo Company, Limited Derives d'amide n-phenyle et d'uree
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US5935951A (en) 1994-09-30 1999-08-10 Novartis Finance Corporation 1-acyl-4-aliphatylaminopiperidine compounds
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
SK79797A3 (en) 1994-12-23 1997-11-05 Thomae Gmbh Dr K Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
AU7492796A (en) * 1995-10-31 1997-05-22 Unichema Chemie Bv Process for the deparaffination of squalane
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859015A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. N-heterocyclic piperazinyl and H-heterocyclic piperazinonyl inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249604A1 (en) 1996-04-03 1997-10-09 Theresa M. Williams Inhibitors of farnesyl-protein transferase
AU706495B2 (en) 1996-04-03 1999-06-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998001133A1 (fr) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273856A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
DE19652273A1 (de) * 1996-12-16 1998-06-18 Basf Ag Monoolefinische C¶5¶-Mononitrile, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
AU741725B2 (en) 1997-08-27 2001-12-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69824037T2 (de) 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
ZA99607B (en) 1998-01-27 1999-07-27 Rhone Poulenc Rorer Pharma Substituted oxoazaheterocyclyl factor xa inhibitors.
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPR237301A0 (en) * 2001-01-02 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
JP2004501903A (ja) * 2000-06-29 2004-01-22 藤沢薬品工業株式会社 ベンズヒドリル誘導体
ATE338564T1 (de) 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20040029865A1 (en) 2002-05-23 2004-02-12 Acker Brad A. Bis-arylsulfones
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
IS2402B (is) 2008-09-15
JP4488743B2 (ja) 2010-06-23
IL162765A (en) 2012-04-30
MXPA04006791A (es) 2004-12-06
TWI291466B (en) 2007-12-21
NO20043239D0 (no) 2004-08-02
AU2003205753B8 (en) 2010-02-18
WO2003066635A1 (en) 2003-08-14
AU2003205753A1 (en) 2003-09-02
KR101011316B1 (ko) 2011-01-28
CO5611152A2 (es) 2006-02-28
EP1666465B1 (en) 2008-05-07
GB0203020D0 (en) 2002-03-27
US20070099914A1 (en) 2007-05-03
ES2250870T3 (es) 2006-04-16
JP2005524637A (ja) 2005-08-18
US20050176715A1 (en) 2005-08-11
DE60302137D1 (de) 2005-12-08
CA2475619A1 (en) 2003-08-14
DE60302137T2 (de) 2006-07-20
IS7382A (is) 2004-08-04
HK1072251A1 (en) 2005-08-19
AU2003205753B9 (en) 2010-03-04
PL373532A1 (en) 2005-09-05
RU2336276C2 (ru) 2008-10-20
EP1472256B1 (en) 2005-11-02
NO329379B1 (no) 2010-10-04
MY130411A (en) 2007-06-29
ZA200404842B (en) 2005-09-28
BRPI0307123B8 (pt) 2021-05-25
PL211082B1 (pl) 2012-04-30
AR038818A1 (es) 2005-01-26
ATE308543T1 (de) 2005-11-15
US7189713B2 (en) 2007-03-13
IL162765A0 (en) 2005-11-20
DK1472256T3 (da) 2006-03-20
CN1319973C (zh) 2007-06-06
BRPI0307123B1 (pt) 2018-06-19
US7652012B2 (en) 2010-01-26
AU2003205753B2 (en) 2010-01-07
EP1666465A1 (en) 2006-06-07
DE60320865D1 (de) 2008-06-19
ATE394375T1 (de) 2008-05-15
US20100152446A1 (en) 2010-06-17
TW200400192A (en) 2004-01-01
NZ533785A (en) 2007-05-31
CA2475619C (en) 2011-04-12
RU2004126957A (ru) 2005-04-20
CN1628115A (zh) 2005-06-15
EP1472256A1 (en) 2004-11-03
NO20043239L (no) 2004-08-02
ES2304660T3 (es) 2008-10-16
KR20040086354A (ko) 2004-10-08

Similar Documents

Publication Publication Date Title
BR0307123A (pt) Derivados de piperazina
BR0114637A (pt) Compostos quìmicos
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
ATE518564T1 (de) Benzamide- und pyridylamide-derivate als antibakterielle mittel
ME00353B (me) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
NO20051892L (no) Ny forbindelse
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
AR031627A1 (es) Activadores heteroaromaticos fusionados de la glucoquinasa
CY1107775T1 (el) Παραγωγα κουιναζολινης φωσφονοξεως και η φαρμακευτικη χρηση τους
ATE302775T1 (de) Carbolinderivate
JO2354B1 (en) New derivatives of aromatic fluoroglycosides and drugs containing these compounds and their use
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DK1585493T3 (da) Triazinderivater som UV-absorbenter
BR0314843A (pt) Novo composto
DE602005010607D1 (de) Zyklosporinanalog
WO2003066621A8 (en) Piperidine derivatives and their use as antagonists of tachykinins
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR0012463A (pt) N-aralquil aminas cìclicas antipsicóticas
ATE380810T1 (de) Protein-tyrosine-kinase-inhibitoren
ATE360422T1 (de) Tetrazyklische verbindungen als pde5-inhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: GLAXO GROUP LIMITED (GB)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130082869/RJ DE 15/10/2013, E NECESSARIO APRESENTAR O DOCUMENTO DE TRANSFERENCIA COM A DEVIDA LEGALIZACAO CONSULAR.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: GLAXO GROUP LIMITED (GB)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860140127109 DE 28/07/2014, E NECESSARIO APRESENTAR O DOCUMENTO DE TRANSFERENCIA COM A DEVIDA LEGALIZACAO CONSULAR.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GLAXO GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NERRE THERAPEUTICS LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/02/2023